Metformina Pharma Combix

Metformin, the active ingredient in Metformina Pharma Combix, is a biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels. It works by targeting hepatic glucose output and peripheral insulin sensitivity.

GNH USA supplies Metformina Pharma Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antidiabetic medication for health‑care systems across multiple regions. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity.

Metformin is used in the management of disorders related to glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes by reducing hepatic glucose output. - Polycystic ovary syndrome: improves insulin sensitivity, which can aid in menstrual regularity and ovulation.

Metformin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or flatulence. - Diarrhea: loose stools occurring especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe hypoglycemia: typically when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term therapy. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Skin rash: including severe cutaneous reactions. - Pancreatitis: inflammation of the pancreas.

When prescribing Metformina Pharma Combix, clinicians should consider several safety measures.

- Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Monitor blood glucose: adjust therapy based on glycemic response and avoid hypoglycemia. - Hepatic function evaluation: check liver enzymes in patients with existing liver disease. - Use caution in elderly: increased risk of renal impairment and dehydration. - Avoid in severe heart failure: risk of lactic acidosis is heightened. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina Pharma Combix can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Alcohol: potentiates lactate accumulation and can lead to acidosis. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: may alter renal function, requiring dose adjustment.